Description: Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Home Page: www.relaytx.com
RLAY Technical Analysis
399 Binney Street
Cambridge,
MA
02139
United States
Phone:
617 370 8837
Officers
| Name | Title |
|---|---|
| Mr. Alexis A. Borisy A.M. | Co-Founder & Independent Chairman |
| Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS | CEO, Pres & Director |
| Dr. Mark Murcko Ph.D. | Co-Founder & Director |
| Mr. Thomas Catinazzo | Chief Financial Officer |
| Mr. Andy Porter | Chief Admin. Officer |
| Mr. Brian R. Adams J.D. | Chief Legal Officer & Sec. |
| Dr. Donald A. Bergstrom M.D., Ph.D. | Pres of R&D |
| Mr. Peter Rahmer | Sr. VP of Corp. Affairs & Investor Relations |
| Dr. Deborah Palestrant Ph.D. | VP of Corp. Devel. & Strategy |
| Mr. Jim Watters Ph.D. | Sr. VP & Head of Late Research |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.1162 |
| Price-to-Sales TTM: | 1224.6414 |
| IPO Date: | 2020-07-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 320 |